Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase II, two-arm, noncomparative screening study of Sacituzumab tirumotecan, an intravenous antibody-drug conjugate (ADC) that targets Trop-1, administered alone or in combination with pembrolizumab, a monoclonal antibody to PD-1 in patients with relapsed clear cell cancers that originated in the ovary, fallopian tube or peritoneal cavity, inclusive of endometriosis (collectively referred to as OCCC throughout the protocol) after previous treatment with anti-PD1 therapy. The regimens will be evaluated separately, and the study is not designed or powered to compare the regimens.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony nowotwór przeziernych komórek jajnika (czysty typ, bez zmieszania z innymi typami)
- •Widoczne zmiany nowotworowe mieralne badaniami obrazowymi
- •Poprzednie leczenie chemioterapią (platinum i taksany) oraz jedną linią leków immunologicznych
- •Ogólny stan zdrowia pozwalający na podjęcie leczenia (ECOG 0-1)
- •Kobieta biologiczna
- •Nie w ciąży, nie karmiąca piersią, gotowa stosować antykoncepcję lub być abstynentką
✗ Disqualifies
- •Przerzuty do mózgu
- •Więcej niż jedna poprzednia linia leczenia lekami immunologicznymi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 16, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Tufts Medical Center
Boston, United States
Trial contact
Neely Center for Clinical Cancer Research
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.